Predicting Response and Toxicity in Patients Receiving Lonafarnib for Breast Cancer

Stopped early

Conditions studied: Breast Cancer

In brief

This is a tumor and serum collection study for patients with advanced breast cancer receiving treatment with lonafarnib.

Key facts

Study ID

NCT01232881

Run by

Hoosier Cancer Research Network

People needed

27

Starts

2009-08-01

Expected to finish

2010-11-01

Last updated by the study team

2011-04-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
• Age > 18 years.
• Planned treatment with lonafarnib for metastatic breast cancer.
• Must consent to have a biopsy performed to obtain fresh tissue or be able to identify a formalin fixed paraffin embedded (FFPE) tissue block in which tumor samples can be obtained to complete the testing for this study.

You may not qualify if…

• Planned treatment with any other treatment regimen

Where it is running

• Indiana University Melvin and Bren Simon Cancer Center — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.